Long-term safety and effectiveness of the Fantom bioresorbable coronary artery scaffold: final results of the FANTOM II trial
EuroIntervention
.
2024 Apr 1;20(7):e453-e456.
doi: 10.4244/EIJ-D-23-00504.
Authors
Matthias Lutz
1
,
Alexandre Abizaid
2
3
,
Emil Nielsen Holck
4
,
Alexandra Lansky
5
,
Didier Carrié
6
,
Joachim Weber-Albers
7
,
Darius Dudek
8
,
Norbert Frey
9
,
Evald Høj Christiansen
4
,
Niels Ramsing Holm
4
,
Gregg W Stone
10
Affiliations
1
Department of Cardiology, University Medical Center Schleswig-Holstein, Campus Kiel, Kiel, Germany.
2
Instituto Dante Pazzanese de Cardiologia, São Paulo, Brazil.
3
Hospital Israelita Albert Einstein, São Paulo, Brazil.
4
Department of Cardiology, Aarhus University Hospital, Skejby, Aarhus, Denmark.
5
Section of Cardiovascular Medicine, Yale School of Medicine, New Haven, CT, USA.
6
Department of Cardiology, University Hospital Rangueil, Toulouse, France.
7
St. Johannes Hospital, Dortmund, Germany.
8
Institute of Cardiology, Jagiellonian University Medical College, University Hospital, Krakow, Poland.
9
Department of Cardiology, University Hospital Heidelberg, Heidelberg, Germany.
10
Columbia University Medical Center/NewYork-Presbyterian Hospital, The Cardiovascular Research Foundation, New York, NY, USA.
PMID:
38562069
PMCID:
PMC10979385
(available on
2025-04-01
)
DOI:
10.4244/EIJ-D-23-00504
No abstract available
Publication types
Clinical Trial
MeSH terms
Absorbable Implants
Coronary Artery Disease* / surgery
Humans
Percutaneous Coronary Intervention*
Prosthesis Design
Sirolimus
Treatment Outcome
Substances
Sirolimus